ARTICLE | Clinical News

AVI BioPharma preclinical data

August 30, 2010 7:00 AM UTC

In rhesus monkeys challenged with a lethal dose of Ebola virus, 3 of 5 monkeys treated in each of the 28 and 40 mg/kg AVI-6002 dose groups survived the infection, while all control monkeys treated with saline died by day 8 post-challenge. Additionally, 4 and 16 mg/kg doses of AVI-6002 led to survival rates of 0% and 20%, respectively. Data were published in Nature Medicine. ...